Literature DB >> 66587

Heterocellular hereditary persistence of fetal haemoglobin and homozygous sickle-cell disease.

G R Serjeant, B E Serjeant, K Mason.   

Abstract

Mesh：

Substances：

Year:  1977        PMID： 66587     DOI： 10.1016/s0140-6736(77)92976-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.

Authors:  Tamara I Pestina; Phillip W Hargrove; Dennis Jay; John T Gray; Kelli M Boyd; Derek A Persons
Journal:  Mol Ther       Date:  2008-12-02       Impact factor: 11.454

2.  Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.

Authors:  Fabrizia Urbinati; Phillip W Hargrove; Sabine Geiger; Zulema Romero; Jennifer Wherley; Michael L Kaufman; Roger P Hollis; Christopher B Chambers; Derek A Persons; Donald B Kohn; Andrew Wilber
Journal:  Exp Hematol       Date:  2015-02-12       Impact factor: 3.084

3.  Heterogeneity of sickle-cell anemia based on a profile of hematological variables.

Authors:  D J Odenheimer; C F Whitten; D L Rucknagel; S A Sarnaik; C F Sing
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

4.  Sickle-cell anaemia in infancy.

Authors: 
Journal:  Br Med J       Date:  1978-06-03

Review 5.  Intravascular hemolysis and the pathophysiology of sickle cell disease.

Authors:  Gregory J Kato; Martin H Steinberg; Mark T Gladwin
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

6.  Genetic regulation of gamma gene expression: study of the interaction of beta-thalassemia with heterocellular HPFH.

Authors:  A M Soummer; U Testa; P Dujardin; A Guerrasio; A Henri; M Gazaix; J Riou; H Rochant; Y Beuzard; J Rosa
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

7.  Amelioration of murine sickle cell disease by nonablative conditioning and γ-globin gene-corrected bone marrow cells.

Authors:  Tamara I Pestina; Phillip W Hargrove; Huifen Zhao; Paul E Mead; Matthew P Smeltzer; Mitchell J Weiss; Andrew Wilber; Derek A Persons
Journal:  Mol Ther Methods Clin Dev       Date:  2015-12-02       Impact factor: 6.698
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.